Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of External Ventricular Drain Duration and Outcomes in Aneurysmal Subarachnoid Hemorrhage: a Single Center Study
Cerebrovascular Disease and Interventional Neurology
P12 - Poster Session 12 (5:30 PM-6:30 PM)
13-003

Hydrocephalus is a common complication following aSAH and is usually treated with EVD. However, there is no consensus on EVD weaning process and duration of cerebrospinal fluid (CSF) drainage.

To determine the association of external ventricular drain (EVD) duration and outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH).

We performed a retrospective cohort study of consecutive patients with aSAH who were admitted to an academic referral center between 2016 and 2021. We included survivors. Binary logistic regression was used to test the association of EVD duration and worse outcome (3-month modified Rankin scale 4-6) and requirement for ventriculoperitoneal shunt (VPS) placement. Multiple linear regression analysis was used to test the association of EVD duration and hospital length of stay.

Of 316 patients with aSAH, 253 patients received EVD on admission for symptomatic hydrocephalus and 204 survivors were included. (mean age 57.9 years [SD 13.8], 62% female, 71% white). VPS was placed in 15% (30/204) prior to hospital discharge. Duration of EVD was longer in patients with worse functional outcome (median 18 days [IQR 13.5-23] vs 12 days [IQR 8-19); p=0.006). Longer EVD duration was associated with higher VPS requirement (odds ratio 1.17 per day, 95% CI 1.09-1.26; p<0.001) after adjustment for age, aneurysm related factors, Hunt and Hess grades, modified Fisher scales and delayed cerebral ischemia. EVD related complications such as infections (2%) and tract hemorrhage (9%) were non-significantly higher in patients with longer EVD duration. (p=0.07) Longer EVD duration was associated with longer hospital length of stay (beta=0.88, 95% CI 0.73-1.04; p<0.001) independent of aSAH complications.

Longer EVD duration can be associated with worse outcomes and higher need for VPS placement and longer hospital length of stay. Further studies are needed to justify early VPS placement in selected patients.

 

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Nicholas S. Potter, MD, PhD (Rhode Island Hospital) Dr. Potter has nothing to disclose.
Christoph Stretz, MD, FAAN (Rhode Island Hospital, Department of Neurology) Dr. Stretz has nothing to disclose.
Linda C. Wendell, MD, FAAN (Mount Auburn Hospital) Dr. Wendell has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. An immediate family member of Dr. Wendell has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. Dr. Wendell has stock in Apple. An immediate family member of Dr. Wendell has stock in Apple.
Jesse Menville Ms. Menville has nothing to disclose.
Karen L. Furie, MD (RIH/Alpert Medical School of Brown Univ) The institution of Dr. Furie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/BMS. Dr. Furie has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ/JNNP. The institution of Dr. Furie has received research support from NINDS.
Bradford B. Thompson, MD (St. Elizabeth’s Medical Center) Dr. Thompson has nothing to disclose.
Ali Mahta, MD (Brown University) Dr. Mahta has nothing to disclose.